Skip to content
Safe in Pregnancy / Safe in Children
  • Living Systematic Review
    • COVID 19
    • Chikungunya
    • Lassa Fever
    • Mpox
    • RSV
      • Effectiveness and immunogenicity outcome
      • Safety outcomes
    • Disease X
  • Resources
  • Steering Committee
  • STAG
  • Development team
  • Spotlights
Close Trigger
  • Living Systematic Review
    • Living Systematic Review Covid-19
    • Pairwise Meta Analyses Covid-19
    • Summary of findings
    • Proportional Meta Analyses
    • Quality Assessment COVID19
    • PRISMA Flow Diagram
  • Resources
  • Steering Committee
  • STAG
  • Development team
Menu
  • Living Systematic Review
    • Living Systematic Review Covid-19
    • Pairwise Meta Analyses Covid-19
    • Summary of findings
    • Proportional Meta Analyses
    • Quality Assessment COVID19
    • PRISMA Flow Diagram
  • Resources
  • Steering Committee
  • STAG
  • Development team

1 st Latin America HIV & Viral Infections Conference (LAHVIC) – Ciudad de México 6 a 9 de agosto de 2025 – Seguridad y Efectividad de las Vacunas COVID-19 en Personas Gestantes: Actualización a Junio 2025 de una Revisión Sistemática Viva y Síntesis de Evidencia del Mundo Real (Presentación oral)

Safe in Pregnancy / Safe in Children

Up-to-date evidence-based information on emerging vaccines in pregnancy and childhood.

Quick Links

  • Home
  • COVID 19
  • Chikungunya
  • Lassa Fever
  • Mpox
  • RSV
  • Effectiveness and immunogenicity outcomes
  • Safety outcomes
  • Disease X
  • Resources
  • Steering Committee
  • STAG
  • Development team
  • Spotlights

Contact Us

Andrea Meyer

ameyer1@tulane.edu

Linkedin
Copyright © 2022. All rights reserved.
Safe in Pregnancy / Safe in Children
  • Living Systematic Review
    • COVID 19
    • Chikungunya
    • Lassa Fever
    • Mpox
    • RSV
      • Effectiveness and immunogenicity outcome
      • Safety outcomes
    • Disease X
  • Resources
  • Steering Committee
  • STAG
  • Development team
  • Spotlights
Menu
  • Living Systematic Review
    • COVID 19
    • Chikungunya
    • Lassa Fever
    • Mpox
    • RSV
      • Effectiveness and immunogenicity outcome
      • Safety outcomes
    • Disease X
  • Resources
  • Steering Committee
  • STAG
  • Development team
  • Spotlights
Contact Us